Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06211751 | A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy | unknown | Phase 1 | 208 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06209671 | INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia | unknown | Phase 1 | 12 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Jan 17, 2024 |
| clinicaltrials |
| NCT04284228 | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | unknown | Phase 1 / Phase 2 | 22 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06205823 | Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM(CAREMM-2305) | unknown | — | 1,600 | Seoul St. Mary's HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06201507 | BV-AVD-R Treatment Children Hodgkin's Lymphoma | unknown | Phase 2 | 44 | Beijing Children's HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06202885 | CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy | unknown | — | 2,500 | Seoul St. Mary's HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06203145 | A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM | unknown | N/A | 30 | Peking University First HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04776265 | RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT | unknown | — | 100 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05078840 | PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors | unknown | — | 75 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05590221 | Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma | unknown | Phase 2 | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05308875 | Efficacy and Safety Evaluation of PD1-BCMA-CART | unknown | N/A | 9 | Bioray LaboratoriesINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05420493 | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma | unknown | Phase 1 | 54 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04776005 | COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies(COVIDVAC OH) | unknown | — | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06188182 | D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia | unknown | — | 60 | Assiut UniversityOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT04090268 | Precision Exercise in Children With Malignant Hemopathies(SportTherapy) | unknown | N/A | 380 | University of Milano BicoccaOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06186986 | CD30 Imaging in Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 20 | University Medical Center GroningenOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT04714827 | Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04715217 | Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT06104553 | A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma | unknown | Phase 1 / Phase 2 | 132 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03505086 | Bleeding In Thrombocytopenia Explained(BITE) | unknown | — | 1,000 | Sanquin-LUMC J.J van Rood Center for Clinical Transfusion ResearchOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06177366 | A New Blood Score for Myelofibrosis Staging(FIBROMOELLE) | unknown | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Dec 20, 2023 | clinicaltrials |
| NCT06177561 | Safety and Efficacy of LPE in Clearing DSA in Patients Who Received Allo-HSCT | unknown | N/A | 38 | Ruijin HospitalOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05757466 | Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma(Prolgo-HL) | unknown | Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT03236129 | Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells(DLI-Boost) | unknown | Phase 3 | 52 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05577364 | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | unknown | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03617666 | Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study(AVENuE) | unknown | Phase 2 | 49 | University College, LondonOTHER | 2 | Dec 12, 2023 | clinicaltrials |
| NCT04407741 | Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT04727008 | CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma | unknown | Phase 1 | 12 | Sichuan UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05846672 | Turkish Cultural Adaptation, Validity and Reliability of the "Gait Outcomes Assessment List" | unknown | — | 200 | Istanbul University - CerrahpasaOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05692713 | Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201) | unknown | — | 320 | University of British ColumbiaOTHER | 2 | Dec 8, 2023 | clinicaltrials |
| NCT06162325 | Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients | unknown | — | 45 | Peking Union Medical College HospitalOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT06160115 | The Role of NK Cells to Detect Blood Infection in ALL. | unknown | — | 56 | Assiut UniversityOTHER | 0 | Dec 7, 2023 | clinicaltrials |
| NCT06160362 | The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) | unknown | N/A | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 7, 2023 | clinicaltrials |
| NCT04877275 | ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | unknown | Phase 2 | 50 | Chunyan Sun, MDOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05113069 | A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas | unknown | Phase 1 | 170 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04372524 | Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study | unknown | — | 350 | University of British ColumbiaOTHER | 2 | Dec 5, 2023 | clinicaltrials |
| NCT04663100 | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | unknown | N/A | 30 | University of TennesseeOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT06154317 | Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM) | unknown | — | 30 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 118 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | unknown | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT03064269 | CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia | unknown | Phase 1 | 10 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03193281 | KISS Study: Kinase Inhibition With Sprycel Start up(KISS) | unknown | Phase 2 | 91 | University of Auckland, New ZealandOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03614858 | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | unknown | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 15 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | unknown | Phase 2 / Phase 3 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04989335 | Bisantrene Combination for Resistant AML | unknown | Phase 2 | 29 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05025150 | Point-of-Care Ultrasound for Pediatric Thoracic Trauma: A Multi-Institutional Trial | unknown | — | 1,020 | Sutter HealthOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05583175 | Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | unknown | Phase 2 | 50 | Xianmin Song, MDOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05803395 | Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. | unknown | — | 954 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05114330 | Secondary Central Nervous System Lymphoma Registry - Charité | unknown | — | 300 | Charite University, Berlin, GermanyOTHER | 1 | Nov 27, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jan 18, 2024source: clinicaltrials